Moreover, HDAC inhibitors also enhance the efficacy of first-line treatments like sorafenib, and can even re-sensitize resistant cells, highlighting their potential as combination agents in HCC treatment (22, 23). Here, HDAC9 is linked to hepatocellular carcinoma.